[Treatment of hyperlipidemia in patients with ischemic heart disease].
Do patients with coronary heart disease benefit from lipid lowering treatment? In the last 20 years clinical research has addressed this question considering 3 different endpoints: clinical events, progression and regression of atherosclerotic plaque, and vascular tone. Eight major secondary prevention trials showed that a 10% reduction in serum cholesterol led to reduction of 15% in the number of all myocardial infarctions. Seven secondary prevention trials based on coronary angiography showed that a 20% serum cholesterol reduction can induce regression and/or reduce progression of plaques in as short as 2 years. In vivo experiments have also shown that coronary spasms are the most common response to various stimulations in hypercholesterolemic individuals; vasodilation is the most common coronary response in subjects with low cholesterol levels.
Clinica Medica, Istituto di Medicina Interna e Malattie Dismetaboliche, II Facoltà di Medicina e Chirurgia, Università degli Studi Federico II, Napoli.
P
P
Pauciullo
C
C
Lirato
C
C
Sapio
M
M
Mancini
D002784:Cholesterol / Q000097:blood; D003324:Coronary Artery Disease / Q000517:prevention & control; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D017202:Myocardial Ischemia / Q000150:complications*; D011379:Prognosis; D014280:Triglycerides / Q000097:blood
D000960:Hypolipidemic Agents; D014280:Triglycerides; D002784:Cholesterol
Il trattamento dell'iperlipidemia nei pazienti affetti da cardiopatia ischemica.